GLG News by ArteFill Users

I totally agree with this article. The conclusions from the FDA are incorrect, and the data appear to indicate that the TCI's are actually protective!!!! In any event it has created a false sense of a problem, where none exists, and decreases the use of these agents, which are safer than the existing...

This article is a good summary of the currently available techniques of excision, subcision, and resurfacing. It does not mention dermal grafting, a technique that I personally use quite often. The maximum correction that one can achieve is 50-70% with a combination of multiple techniques.

Noninvasive modalities are becoming increasingly popularPlasma therapy represents a spin on an old way of rejuvenating skinTo achieve dramatic results, there is a dramatic amount of downtime

This product by Cytochroma is a vitamin D analog which is similar to Dovonex, a product that has been used for 13 years. Its efficacy is modest at best. This product may, repeat may be better, because it activates the vitamin D pathway, and inhibits catabolism of Vitamin D. Whether this makes the product...

This technology is new, but no better than other resurfacing technologies like Sciton and Fraxel. Pain is significant, healing takes weeks, and there are risks as in other resurfacing technologies. The final results are good. A head to head comparison with other technologies is needed.  

Balanced article shows that there are limitations, but essentially it is good technology that reminds us that we need downtime to get significant effects. The promise of no down time lasers has been shown to not be clinically effective. Exiting new technology showcased.

This article has validity in dermatology due to the increased resistance seen in acne. This may have clinical significance in that we may be seeing resistance to therapy in acne patients  after prolonged use.Collagenex corp. is developing non antibiotic medications for acne and rosacea that are...

The hump may have the appearance of having gone but in reality the nose is now larger as the lower areas have been raised. Removing the material is difficult so make sure the patient understands what the downside is.

Although the desires and performance of less invasive or noninvasive procedures has gone up, the stats can be confusing. Firstly the non or less invasive procedures do not hold up as long and do not give as much of an improvement, patients need to be told it will be a subtle change, and they need to...

The open label trial results for the product Relieva from Allegiance Equity Corp. are encouraging. However the trials need to be double blinded, and with a much larger number of patients. If the product can be compared to a low- mid potency topical steroid in efficacy, then it will be successful. Homeopathic...